Benefits for psoriasis practices: New phase III data shows subcutaneous methotrexate’s favorable long-term efficacy and safety profile.

Medac hosted  a satellite symposium at the EADV conference 2016 in Vienna with the title METOP study – evaluation of subcutaneous methotrexate for psoriasis patients.

Satellite symposium took place on Friday 30th of September, 2016 at Hall L3, floor 1.

Invitation to medac EADV 2016

medac press release EADV2016

More information about the congress